Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
Identifieur interne : 000540 ( PascalFrancis/Corpus ); précédent : 000539; suivant : 000541Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
Auteurs : Raymond H. See ; Alexander N. Zakhartchouk ; Martin Petric ; David J. Lawrence ; Catherine P. Y. Mok ; Robert J. Hogan ; Thomas Rowe ; Lois A. Zitzow ; Karuna P. Karunakaran ; Mary M. Hilt ; Frank L. Graham ; Ludvik Prevec ; James B. Mahony ; Chetna Sharon ; Thierry C. Auperin ; James M. Rini ; Aubrey J. Tingle ; David W. Scheifele ; Danuta M. Skowronski ; David M. Patrick ; Thomas G. Voss ; Lorne A. Babiuk ; Jack Gauldie ; Rachel L. Roper ; Robert C. Brunham ; B. Brett FinlaySource :
- Journal of general virology [ 0022-1317 ] ; 2006.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by /?-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 06-0150208 INIST |
|---|---|
| ET : | Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus |
| AU : | SEE (Raymond H.); ZAKHARTCHOUK (Alexander N.); PETRIC (Martin); LAWRENCE (David J.); MOK (Catherine P. Y.); HOGAN (Robert J.); ROWE (Thomas); ZITZOW (Lois A.); KARUNAKARAN (Karuna P.); HILT (Mary M.); GRAHAM (Frank L.); PREVEC (Ludvik); MAHONY (James B.); SHARON (Chetna); AUPERIN (Thierry C.); RINI (James M.); TINGLE (Aubrey J.); SCHEIFELE (David W.); SKOWRONSKI (Danuta M.); PATRICK (David M.); VOSS (Thomas G.); BABIUK (Lorne A.); GAULDIE (Jack); ROPER (Rachel L.); BRUNHAM (Robert C.); FINLAY (B. Brett) |
| AF : | University of British Columbia Centre for Disease Control/Vancouver, BC V5Z 4R4/Canada (1 aut., 3 aut., 4 aut., 5 aut., 9 aut., 19 aut., 20 aut., 25 aut.); Vaccine and Infectious Disease Organization, University of Saskatchewan/Saskatoon, SK S7N 5E3/Canada (2 aut., 22 aut.); Emerging Pathogens Department, Southern Research Institute/Birmingham, AL 35205/Etats-Unis (6 aut., 7 aut., 8 aut., 21 aut.); Departments of Pathology and Molecular Medicine and Biology, McMaster University/Hamilton, ON L8N 3Z5/Canada (10 aut., 11 aut., 12 aut., 13 aut., 23 aut.); Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto/Toronto, ON M5S 1A8/Canada (14 aut., 15 aut., 16 aut.); Michael Smith Foundation for Health Research/Vancouver, BC V6H 3X8/Canada (17 aut.); Vaccine Evaluation Centre, British Columbia Institute for Children's and Women's Health, BC Children's Hospital/Vancouver, BC V6H 3V4/Canada (18 aut.); Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University/Greenville, NC 27834/Etats-Unis (24 aut.); Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia/Vancouver, BC V6T 1Z3/Canada (26 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Journal of general virology; ISSN 0022-1317; Coden JGVIAY; Royaume-Uni; Da. 2006; Vol. 87; No. p.3; Pp. 641-650; Bibl. 1 p.1/2 |
| LA : | Anglais |
| EA : | Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by /?-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection. |
| CC : | 002A05C10; 002A05C07 |
| FD : | Souris; Virus syndrome respiratoire aigu sévère; Vaccin; Microbiologie; Virologie; Syndrome respiratoire aigu sévère |
| FG : | Rodentia; Mammalia; Vertebrata; Coronavirus; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie |
| ED : | Mouse; Severe acute respiratory syndrome virus; Vaccine; Microbiology; Virology; Severe acute respiratory syndrome |
| EG : | Rodentia; Mammalia; Vertebrata; Coronavirus; Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection; Lung disease |
| SD : | Ratón; Severe acute respiratory syndrome virus; Vacuna; Microbiología; Virología; Síndrome respiratorio agudo severo |
| LO : | INIST-13533.354000132969430180 |
| ID : | 06-0150208 |
Links to Exploration step
Pascal:06-0150208Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus</title><author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H." last="See">Raymond H. See</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zakhartchouk, Alexander N" sort="Zakhartchouk, Alexander N" uniqKey="Zakhartchouk A" first="Alexander N." last="Zakhartchouk">Alexander N. Zakhartchouk</name><affiliation><inist:fA14 i1="02"><s1>Vaccine and Infectious Disease Organization, University of Saskatchewan</s1><s2>Saskatoon, SK S7N 5E3</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J." last="Lawrence">David J. Lawrence</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P. Y." last="Mok">Catherine P. Y. Mok</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J." last="Hogan">Robert J. Hogan</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A." last="Zitzow">Lois A. Zitzow</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P." last="Karunakaran">Karuna P. Karunakaran</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hilt, Mary M" sort="Hilt, Mary M" uniqKey="Hilt M" first="Mary M." last="Hilt">Mary M. Hilt</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Graham, Frank L" sort="Graham, Frank L" uniqKey="Graham F" first="Frank L." last="Graham">Frank L. Graham</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Prevec, Ludvik" sort="Prevec, Ludvik" uniqKey="Prevec L" first="Ludvik" last="Prevec">Ludvik Prevec</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mahony, James B" sort="Mahony, James B" uniqKey="Mahony J" first="James B." last="Mahony">James B. Mahony</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sharon, Chetna" sort="Sharon, Chetna" uniqKey="Sharon C" first="Chetna" last="Sharon">Chetna Sharon</name><affiliation><inist:fA14 i1="05"><s1>Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto</s1><s2>Toronto, ON M5S 1A8</s2><s3>CAN</s3><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Auperin, Thierry C" sort="Auperin, Thierry C" uniqKey="Auperin T" first="Thierry C." last="Auperin">Thierry C. Auperin</name><affiliation><inist:fA14 i1="05"><s1>Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto</s1><s2>Toronto, ON M5S 1A8</s2><s3>CAN</s3><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rini, James M" sort="Rini, James M" uniqKey="Rini J" first="James M." last="Rini">James M. Rini</name><affiliation><inist:fA14 i1="05"><s1>Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto</s1><s2>Toronto, ON M5S 1A8</s2><s3>CAN</s3><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tingle, Aubrey J" sort="Tingle, Aubrey J" uniqKey="Tingle A" first="Aubrey J." last="Tingle">Aubrey J. Tingle</name><affiliation><inist:fA14 i1="06"><s1>Michael Smith Foundation for Health Research</s1><s2>Vancouver, BC V6H 3X8</s2><s3>CAN</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Scheifele, David W" sort="Scheifele, David W" uniqKey="Scheifele D" first="David W." last="Scheifele">David W. Scheifele</name><affiliation><inist:fA14 i1="07"><s1>Vaccine Evaluation Centre, British Columbia Institute for Children's and Women's Health, BC Children's Hospital</s1><s2>Vancouver, BC V6H 3V4</s2><s3>CAN</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M." last="Skowronski">Danuta M. Skowronski</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M." last="Patrick">David M. Patrick</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G." last="Voss">Thomas G. Voss</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Babiuk, Lorne A" sort="Babiuk, Lorne A" uniqKey="Babiuk L" first="Lorne A." last="Babiuk">Lorne A. Babiuk</name><affiliation><inist:fA14 i1="02"><s1>Vaccine and Infectious Disease Organization, University of Saskatchewan</s1><s2>Saskatoon, SK S7N 5E3</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L." last="Roper">Rachel L. Roper</name><affiliation><inist:fA14 i1="08"><s1>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University</s1><s2>Greenville, NC 27834</s2><s3>USA</s3><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C." last="Brunham">Robert C. Brunham</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B. Brett" last="Finlay">B. Brett Finlay</name><affiliation><inist:fA14 i1="09"><s1>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia</s1><s2>Vancouver, BC V6T 1Z3</s2><s3>CAN</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">06-0150208</idno><date when="2006">2006</date><idno type="stanalyst">PASCAL 06-0150208 INIST</idno><idno type="RBID">Pascal:06-0150208</idno><idno type="wicri:Area/PascalFrancis/Corpus">000540</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus</title><author><name sortKey="See, Raymond H" sort="See, Raymond H" uniqKey="See R" first="Raymond H." last="See">Raymond H. See</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zakhartchouk, Alexander N" sort="Zakhartchouk, Alexander N" uniqKey="Zakhartchouk A" first="Alexander N." last="Zakhartchouk">Alexander N. Zakhartchouk</name><affiliation><inist:fA14 i1="02"><s1>Vaccine and Infectious Disease Organization, University of Saskatchewan</s1><s2>Saskatoon, SK S7N 5E3</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Petric, Martin" sort="Petric, Martin" uniqKey="Petric M" first="Martin" last="Petric">Martin Petric</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Lawrence, David J" sort="Lawrence, David J" uniqKey="Lawrence D" first="David J." last="Lawrence">David J. Lawrence</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mok, Catherine P Y" sort="Mok, Catherine P Y" uniqKey="Mok C" first="Catherine P. Y." last="Mok">Catherine P. Y. Mok</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hogan, Robert J" sort="Hogan, Robert J" uniqKey="Hogan R" first="Robert J." last="Hogan">Robert J. Hogan</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rowe, Thomas" sort="Rowe, Thomas" uniqKey="Rowe T" first="Thomas" last="Rowe">Thomas Rowe</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Zitzow, Lois A" sort="Zitzow, Lois A" uniqKey="Zitzow L" first="Lois A." last="Zitzow">Lois A. Zitzow</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Karunakaran, Karuna P" sort="Karunakaran, Karuna P" uniqKey="Karunakaran K" first="Karuna P." last="Karunakaran">Karuna P. Karunakaran</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Hilt, Mary M" sort="Hilt, Mary M" uniqKey="Hilt M" first="Mary M." last="Hilt">Mary M. Hilt</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Graham, Frank L" sort="Graham, Frank L" uniqKey="Graham F" first="Frank L." last="Graham">Frank L. Graham</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Prevec, Ludvik" sort="Prevec, Ludvik" uniqKey="Prevec L" first="Ludvik" last="Prevec">Ludvik Prevec</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Mahony, James B" sort="Mahony, James B" uniqKey="Mahony J" first="James B." last="Mahony">James B. Mahony</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Sharon, Chetna" sort="Sharon, Chetna" uniqKey="Sharon C" first="Chetna" last="Sharon">Chetna Sharon</name><affiliation><inist:fA14 i1="05"><s1>Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto</s1><s2>Toronto, ON M5S 1A8</s2><s3>CAN</s3><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Auperin, Thierry C" sort="Auperin, Thierry C" uniqKey="Auperin T" first="Thierry C." last="Auperin">Thierry C. Auperin</name><affiliation><inist:fA14 i1="05"><s1>Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto</s1><s2>Toronto, ON M5S 1A8</s2><s3>CAN</s3><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Rini, James M" sort="Rini, James M" uniqKey="Rini J" first="James M." last="Rini">James M. Rini</name><affiliation><inist:fA14 i1="05"><s1>Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto</s1><s2>Toronto, ON M5S 1A8</s2><s3>CAN</s3><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Tingle, Aubrey J" sort="Tingle, Aubrey J" uniqKey="Tingle A" first="Aubrey J." last="Tingle">Aubrey J. Tingle</name><affiliation><inist:fA14 i1="06"><s1>Michael Smith Foundation for Health Research</s1><s2>Vancouver, BC V6H 3X8</s2><s3>CAN</s3><sZ>17 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Scheifele, David W" sort="Scheifele, David W" uniqKey="Scheifele D" first="David W." last="Scheifele">David W. Scheifele</name><affiliation><inist:fA14 i1="07"><s1>Vaccine Evaluation Centre, British Columbia Institute for Children's and Women's Health, BC Children's Hospital</s1><s2>Vancouver, BC V6H 3V4</s2><s3>CAN</s3><sZ>18 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Skowronski, Danuta M" sort="Skowronski, Danuta M" uniqKey="Skowronski D" first="Danuta M." last="Skowronski">Danuta M. Skowronski</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Patrick, David M" sort="Patrick, David M" uniqKey="Patrick D" first="David M." last="Patrick">David M. Patrick</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Voss, Thomas G" sort="Voss, Thomas G" uniqKey="Voss T" first="Thomas G." last="Voss">Thomas G. Voss</name><affiliation><inist:fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Babiuk, Lorne A" sort="Babiuk, Lorne A" uniqKey="Babiuk L" first="Lorne A." last="Babiuk">Lorne A. Babiuk</name><affiliation><inist:fA14 i1="02"><s1>Vaccine and Infectious Disease Organization, University of Saskatchewan</s1><s2>Saskatoon, SK S7N 5E3</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>22 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Gauldie, Jack" sort="Gauldie, Jack" uniqKey="Gauldie J" first="Jack" last="Gauldie">Jack Gauldie</name><affiliation><inist:fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Roper, Rachel L" sort="Roper, Rachel L" uniqKey="Roper R" first="Rachel L." last="Roper">Rachel L. Roper</name><affiliation><inist:fA14 i1="08"><s1>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University</s1><s2>Greenville, NC 27834</s2><s3>USA</s3><sZ>24 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Brunham, Robert C" sort="Brunham, Robert C" uniqKey="Brunham R" first="Robert C." last="Brunham">Robert C. Brunham</name><affiliation><inist:fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Finlay, B Brett" sort="Finlay, B Brett" uniqKey="Finlay B" first="B. Brett" last="Finlay">B. Brett Finlay</name><affiliation><inist:fA14 i1="09"><s1>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia</s1><s2>Vancouver, BC V6T 1Z3</s2><s3>CAN</s3><sZ>26 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Journal of general virology</title><title level="j" type="abbreviated">J. gen. virol.</title><idno type="ISSN">0022-1317</idno><imprint><date when="2006">2006</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Journal of general virology</title><title level="j" type="abbreviated">J. gen. virol.</title><idno type="ISSN">0022-1317</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Microbiology</term><term>Mouse</term><term>Severe acute respiratory syndrome</term><term>Severe acute respiratory syndrome virus</term><term>Vaccine</term><term>Virology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Souris</term><term>Virus syndrome respiratoire aigu sévère</term><term>Vaccin</term><term>Microbiologie</term><term>Virologie</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by /?-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0022-1317</s0></fA01><fA02 i1="01"><s0>JGVIAY</s0></fA02><fA03 i2="1"><s0>J. gen. virol.</s0></fA03><fA05><s2>87</s2></fA05><fA06><s3>p.3</s3></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus</s1></fA08><fA11 i1="01" i2="1"><s1>SEE (Raymond H.)</s1></fA11><fA11 i1="02" i2="1"><s1>ZAKHARTCHOUK (Alexander N.)</s1></fA11><fA11 i1="03" i2="1"><s1>PETRIC (Martin)</s1></fA11><fA11 i1="04" i2="1"><s1>LAWRENCE (David J.)</s1></fA11><fA11 i1="05" i2="1"><s1>MOK (Catherine P. Y.)</s1></fA11><fA11 i1="06" i2="1"><s1>HOGAN (Robert J.)</s1></fA11><fA11 i1="07" i2="1"><s1>ROWE (Thomas)</s1></fA11><fA11 i1="08" i2="1"><s1>ZITZOW (Lois A.)</s1></fA11><fA11 i1="09" i2="1"><s1>KARUNAKARAN (Karuna P.)</s1></fA11><fA11 i1="10" i2="1"><s1>HILT (Mary M.)</s1></fA11><fA11 i1="11" i2="1"><s1>GRAHAM (Frank L.)</s1></fA11><fA11 i1="12" i2="1"><s1>PREVEC (Ludvik)</s1></fA11><fA11 i1="13" i2="1"><s1>MAHONY (James B.)</s1></fA11><fA11 i1="14" i2="1"><s1>SHARON (Chetna)</s1></fA11><fA11 i1="15" i2="1"><s1>AUPERIN (Thierry C.)</s1></fA11><fA11 i1="16" i2="1"><s1>RINI (James M.)</s1></fA11><fA11 i1="17" i2="1"><s1>TINGLE (Aubrey J.)</s1></fA11><fA11 i1="18" i2="1"><s1>SCHEIFELE (David W.)</s1></fA11><fA11 i1="19" i2="1"><s1>SKOWRONSKI (Danuta M.)</s1></fA11><fA11 i1="20" i2="1"><s1>PATRICK (David M.)</s1></fA11><fA11 i1="21" i2="1"><s1>VOSS (Thomas G.)</s1></fA11><fA11 i1="22" i2="1"><s1>BABIUK (Lorne A.)</s1></fA11><fA11 i1="23" i2="1"><s1>GAULDIE (Jack)</s1></fA11><fA11 i1="24" i2="1"><s1>ROPER (Rachel L.)</s1></fA11><fA11 i1="25" i2="1"><s1>BRUNHAM (Robert C.)</s1></fA11><fA11 i1="26" i2="1"><s1>FINLAY (B. Brett)</s1></fA11><fA14 i1="01"><s1>University of British Columbia Centre for Disease Control</s1><s2>Vancouver, BC V5Z 4R4</s2><s3>CAN</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>9 aut.</sZ><sZ>19 aut.</sZ><sZ>20 aut.</sZ><sZ>25 aut.</sZ></fA14><fA14 i1="02"><s1>Vaccine and Infectious Disease Organization, University of Saskatchewan</s1><s2>Saskatoon, SK S7N 5E3</s2><s3>CAN</s3><sZ>2 aut.</sZ><sZ>22 aut.</sZ></fA14><fA14 i1="03"><s1>Emerging Pathogens Department, Southern Research Institute</s1><s2>Birmingham, AL 35205</s2><s3>USA</s3><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ><sZ>21 aut.</sZ></fA14><fA14 i1="04"><s1>Departments of Pathology and Molecular Medicine and Biology, McMaster University</s1><s2>Hamilton, ON L8N 3Z5</s2><s3>CAN</s3><sZ>10 aut.</sZ><sZ>11 aut.</sZ><sZ>12 aut.</sZ><sZ>13 aut.</sZ><sZ>23 aut.</sZ></fA14><fA14 i1="05"><s1>Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto</s1><s2>Toronto, ON M5S 1A8</s2><s3>CAN</s3><sZ>14 aut.</sZ><sZ>15 aut.</sZ><sZ>16 aut.</sZ></fA14><fA14 i1="06"><s1>Michael Smith Foundation for Health Research</s1><s2>Vancouver, BC V6H 3X8</s2><s3>CAN</s3><sZ>17 aut.</sZ></fA14><fA14 i1="07"><s1>Vaccine Evaluation Centre, British Columbia Institute for Children's and Women's Health, BC Children's Hospital</s1><s2>Vancouver, BC V6H 3V4</s2><s3>CAN</s3><sZ>18 aut.</sZ></fA14><fA14 i1="08"><s1>Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University</s1><s2>Greenville, NC 27834</s2><s3>USA</s3><sZ>24 aut.</sZ></fA14><fA14 i1="09"><s1>Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia</s1><s2>Vancouver, BC V6T 1Z3</s2><s3>CAN</s3><sZ>26 aut.</sZ></fA14><fA20><s1>641-650</s1></fA20><fA21><s1>2006</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>13533</s2><s5>354000132969430180</s5></fA43><fA44><s0>0000</s0><s1>© 2006 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>1 p.1/2</s0></fA45><fA47 i1="01" i2="1"><s0>06-0150208</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Journal of general virology</s0></fA64><fA66 i1="01"><s0>GBR</s0></fA66><fC01 i1="01" l="ENG"><s0>Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by /?-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.</s0></fC01><fC02 i1="01" i2="X"><s0>002A05C10</s0></fC02><fC02 i1="02" i2="X"><s0>002A05C07</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Souris</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Mouse</s0><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Ratón</s0><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Virus syndrome respiratoire aigu sévère</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Severe acute respiratory syndrome virus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Severe acute respiratory syndrome virus</s0><s2>NW</s2><s5>02</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Vaccin</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Vaccine</s0><s5>05</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Vacuna</s0><s5>05</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Microbiologie</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Microbiology</s0><s5>06</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Microbiología</s0><s5>06</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Virologie</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Virology</s0><s5>07</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Virología</s0><s5>07</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Syndrome respiratoire aigu sévère</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Severe acute respiratory syndrome</s0><s2>NM</s2><s5>14</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Síndrome respiratorio agudo severo</s0><s2>NM</s2><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Rodentia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Mammalia</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Vertebrata</s0><s2>NS</s2></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Coronavirus</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Coronaviridae</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Nidovirales</s0><s2>NW</s2></fC07><fC07 i1="07" i2="X" l="FRE"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="07" i2="X" l="ENG"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="07" i2="X" l="SPA"><s0>Virus</s0><s2>NW</s2></fC07><fC07 i1="08" i2="X" l="FRE"><s0>Appareil respiratoire pathologie</s0><s5>13</s5></fC07><fC07 i1="08" i2="X" l="ENG"><s0>Respiratory disease</s0><s5>13</s5></fC07><fC07 i1="08" i2="X" l="SPA"><s0>Aparato respiratorio patología</s0><s5>13</s5></fC07><fC07 i1="09" i2="X" l="FRE"><s0>Virose</s0></fC07><fC07 i1="09" i2="X" l="ENG"><s0>Viral disease</s0></fC07><fC07 i1="09" i2="X" l="SPA"><s0>Virosis</s0></fC07><fC07 i1="10" i2="X" l="FRE"><s0>Infection</s0></fC07><fC07 i1="10" i2="X" l="ENG"><s0>Infection</s0></fC07><fC07 i1="10" i2="X" l="SPA"><s0>Infección</s0></fC07><fC07 i1="11" i2="X" l="FRE"><s0>Poumon pathologie</s0><s5>16</s5></fC07><fC07 i1="11" i2="X" l="ENG"><s0>Lung disease</s0><s5>16</s5></fC07><fC07 i1="11" i2="X" l="SPA"><s0>Pulmón patología</s0><s5>16</s5></fC07><fN21><s1>093</s1></fN21><fN44 i1="01"><s1>OTO</s1></fN44><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 06-0150208 INIST</NO><ET>Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus</ET><AU>SEE (Raymond H.); ZAKHARTCHOUK (Alexander N.); PETRIC (Martin); LAWRENCE (David J.); MOK (Catherine P. Y.); HOGAN (Robert J.); ROWE (Thomas); ZITZOW (Lois A.); KARUNAKARAN (Karuna P.); HILT (Mary M.); GRAHAM (Frank L.); PREVEC (Ludvik); MAHONY (James B.); SHARON (Chetna); AUPERIN (Thierry C.); RINI (James M.); TINGLE (Aubrey J.); SCHEIFELE (David W.); SKOWRONSKI (Danuta M.); PATRICK (David M.); VOSS (Thomas G.); BABIUK (Lorne A.); GAULDIE (Jack); ROPER (Rachel L.); BRUNHAM (Robert C.); FINLAY (B. Brett)</AU><AF>University of British Columbia Centre for Disease Control/Vancouver, BC V5Z 4R4/Canada (1 aut., 3 aut., 4 aut., 5 aut., 9 aut., 19 aut., 20 aut., 25 aut.); Vaccine and Infectious Disease Organization, University of Saskatchewan/Saskatoon, SK S7N 5E3/Canada (2 aut., 22 aut.); Emerging Pathogens Department, Southern Research Institute/Birmingham, AL 35205/Etats-Unis (6 aut., 7 aut., 8 aut., 21 aut.); Departments of Pathology and Molecular Medicine and Biology, McMaster University/Hamilton, ON L8N 3Z5/Canada (10 aut., 11 aut., 12 aut., 13 aut., 23 aut.); Departments of Molecular and Medical Genetics and Microbiology and Biochemistry, University of Toronto/Toronto, ON M5S 1A8/Canada (14 aut., 15 aut., 16 aut.); Michael Smith Foundation for Health Research/Vancouver, BC V6H 3X8/Canada (17 aut.); Vaccine Evaluation Centre, British Columbia Institute for Children's and Women's Health, BC Children's Hospital/Vancouver, BC V6H 3V4/Canada (18 aut.); Brody School of Medicine, Department of Microbiology and Immunology, East Carolina University/Greenville, NC 27834/Etats-Unis (24 aut.); Michael Smith Laboratories and Departments of Biochemistry and Molecular Biology and Microbiology and Immunology, University of British Columbia/Vancouver, BC V6T 1Z3/Canada (26 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Journal of general virology; ISSN 0022-1317; Coden JGVIAY; Royaume-Uni; Da. 2006; Vol. 87; No. p.3; Pp. 641-650; Bibl. 1 p.1/2</SO><LA>Anglais</LA><EA>Two different severe acute respiratory syndrome (SARS) vaccine strategies were evaluated for their ability to protect against live SARS coronavirus (CoV) challenge in a murine model of infection. A whole killed (inactivated by /?-propiolactone) SARS-CoV vaccine and a combination of two adenovirus-based vectors, one expressing the nucleocapsid (N) and the other expressing the spike (S) protein (collectively designated Ad S/N), were evaluated for the induction of serum neutralizing antibodies and cellular immune responses and their ability to protect against pulmonary SARS-CoV replication. The whole killed virus (WKV) vaccine given subcutaneously to 129S6/SvEv mice was more effective than the Ad S/N vaccine administered either intranasally or intramuscularly in inhibiting SARS-CoV replication in the murine respiratory tract. This protective ability of the WKV vaccine correlated with the induction of high serum neutralizing-antibody titres, but not with cellular immune responses as measured by gamma interferon secretion by mouse splenocytes. Titres of serum neutralizing antibodies induced by the Ad S/N vaccine administered intranasally or intramuscularly were significantly lower than those induced by the WKV vaccine. However, Ad S/N administered intranasally, but not intramuscularly, significantly limited SARS-CoV replication in the lungs. Among the vaccine groups, SARS-CoV-specific IgA was found only in the sera of mice immunized intranasally with Ad S/N, suggesting that mucosal immunity may play a role in protection for the intranasal Ad S/N delivery system. Finally, the sera of vaccinated mice contained antibodies to S, further suggesting a role for this protein in conferring protective immunity against SARS-CoV infection.</EA><CC>002A05C10; 002A05C07</CC><FD>Souris; Virus syndrome respiratoire aigu sévère; Vaccin; Microbiologie; Virologie; Syndrome respiratoire aigu sévère</FD><FG>Rodentia; Mammalia; Vertebrata; Coronavirus; Coronaviridae; Nidovirales; Virus; Appareil respiratoire pathologie; Virose; Infection; Poumon pathologie</FG><ED>Mouse; Severe acute respiratory syndrome virus; Vaccine; Microbiology; Virology; Severe acute respiratory syndrome</ED><EG>Rodentia; Mammalia; Vertebrata; Coronavirus; Coronaviridae; Nidovirales; Virus; Respiratory disease; Viral disease; Infection; Lung disease</EG><SD>Ratón; Severe acute respiratory syndrome virus; Vacuna; Microbiología; Virología; Síndrome respiratorio agudo severo</SD><LO>INIST-13533.354000132969430180</LO><ID>06-0150208</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000540 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000540 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:06-0150208
|texte= Comparative evaluation of two severe acute respiratory syndrome (SARS) vaccine candidates in mice challenged with SARS coronavirus
}}
| This area was generated with Dilib version V0.6.33. |  |